BACKGROUND: Guidelines for the diagnosis and grading of lymphocytic bronchiolitis (LB) have been available for more than a decade, but agreement is lacking concerning the clinical implications of this histologic finding. OBJECTIVES: Study goals were to describe the overall prevalence and incidence of LB in a consecutive cohort of lung transplant recipients and identify risk factors for the onset, frequency, and severity of LB. METHODS: A retrospective analysis was done of 2,697 transbronchial biopsy (TBB) specimens obtained during the first 2 years after transplantation from 299 consecutive patients who underwent transplantation between 1996 and 2006. RESULTS: Full diameter membranous bronchioli were missing in approximately 30% of TBB specimens. The proportion of patients demonstrating LB remained constant during follow-up (trend test, p = 0.2). The cumulative incidence of LB (>or=B2) was 33%, 53%, 62%, and 68% at 1-, 3-, 6-, and 12-months, respectively. Approximately one-quarter and one-half of the patients had a second episode of >or=B2 within 3 months and 2-years of transplantation, respectively. Exposure to LB during the first 2 years after transplantation was independently associated with the frequency and/or severity of acute cellular rejection (p < 0.0001). The choice between anti-thymocyte globulin or daclizumab induction did not alter the overall frequency and/or severity of LB (p = 0.7). LB grade B2 or higher was associated with increased histologic bronchiolitis obliterans (odds ratio, 3.3, 95% confidence interval, 1.5-6.9, p = 0.001). CONCLUSIONS: The frequency and severity of LB was associated with the occurrence and severity of acute cellular rejection.
BACKGROUND: Guidelines for the diagnosis and grading of lymphocytic bronchiolitis (LB) have been available for more than a decade, but agreement is lacking concerning the clinical implications of this histologic finding. OBJECTIVES: Study goals were to describe the overall prevalence and incidence of LB in a consecutive cohort of lung transplant recipients and identify risk factors for the onset, frequency, and severity of LB. METHODS: A retrospective analysis was done of 2,697 transbronchial biopsy (TBB) specimens obtained during the first 2 years after transplantation from 299 consecutive patients who underwent transplantation between 1996 and 2006. RESULTS: Full diameter membranous bronchioli were missing in approximately 30% of TBB specimens. The proportion of patients demonstrating LB remained constant during follow-up (trend test, p = 0.2). The cumulative incidence of LB (>or=B2) was 33%, 53%, 62%, and 68% at 1-, 3-, 6-, and 12-months, respectively. Approximately one-quarter and one-half of the patients had a second episode of >or=B2 within 3 months and 2-years of transplantation, respectively. Exposure to LB during the first 2 years after transplantation was independently associated with the frequency and/or severity of acute cellular rejection (p < 0.0001). The choice between anti-thymocyte globulin or daclizumab induction did not alter the overall frequency and/or severity of LB (p = 0.7). LB grade B2 or higher was associated with increased histologic bronchiolitis obliterans (odds ratio, 3.3, 95% confidence interval, 1.5-6.9, p = 0.001). CONCLUSIONS: The frequency and severity of LB was associated with the occurrence and severity of acute cellular rejection.
Authors: Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn Journal: Semin Immunopathol Date: 2011-01-27 Impact factor: 9.623
Authors: Angela Koutsokera; Pierre J Royer; Jean P Antonietti; Andreas Fritz; Christian Benden; John D Aubert; Adrien Tissot; Karine Botturi; Antoine Roux; Martine L Reynaud-Gaubert; Romain Kessler; Claire Dromer; Sacha Mussot; Hervé Mal; Jean-François Mornex; Romain Guillemain; Christiane Knoop; Marcel Dahan; Paola M Soccal; Johanna Claustre; Edouard Sage; Carine Gomez; Antoine Magnan; Christophe Pison; Laurent P Nicod Journal: Front Med (Lausanne) Date: 2017-07-17
Authors: Laneshia K Tague; Derek E Byers; Ramsey Hachem; Daniel Kreisel; Alexander S Krupnick; Hrishikesh S Kulkarni; Catherine Chen; Howard J Huang; Andrew Gelman Journal: Pharmacogenomics J Date: 2019-04-17 Impact factor: 3.550